China Healthcare Weekly (Nov.17) - TCM VBP New Updates, CR Boya Completes Acquisition of Green Cross
New national TCM VBP round begins with mild price reduction. NHSA to expand TCM VBP with less impact on exclusive varieties/innovative injections....
151 Views
China Healthcare Weekly (July.28)- Ascentage Gets "A Big Gift", CR Boya Acquires Green Cross, Weigao
We noticed some positive updates about Ascentage as competitors' products encountered challenges. China Resources Boya acquires Green Cross....
332 Views
Haier Group to Buy $1.8B Stake in Shanghai RAAS from Grifols – A New Chapter Begins
We analyzed the key points/logic behind Haier's decision to acquire Shanghai RAAS from Grifols. Despite potential risks, it is still a wise move...
491 Views
China Resources Pharmaceutical (3320.HK) - Here Are the Concerns
Pharmaceutical manufacturing business is the key to drive valuation,but the subsidiaries face challenge.CR Pharma should improve its vision of...
353 Views
China Biologic's Privatisation Redux
On Wednesday after market close, China Biologic Products (CBPO US) announced a surprising privatisation bid from a consortium for $120 per ADS. The...
505 Views